Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities

被引：37

作者：

Hagan, H

Latka, MH

Campbell, JV

Golub, ET

Garfein, RS

Thomas, DA

Kapadia, F

Strathdee, SA

机构：

[1] Natl Dev Inst, Ctr Drug Use & HIV Res, New York, NY 10010 USA

[2] Nat Res Inst, Ctr Drug Use & HIV Res, New York, NY 10010 USA

[3] New York Acad Med, Ctr Urban Epidemiol Studies, New York, NY USA

[4] Publ Hlth Seattle & King Cty, HIV AIDS Epidemiol, Seattle, WA USA

[5] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA

[6] Sch Med, Baltimore, MD USA

[7] Univ Calif San Diego, Sch Med, Dept Family & Prevent Med, San Diego, CA 92103 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2006年 / 42卷 / 05期

关键词：

D O I：

10.1086/499951

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Among 404 injection drug users aged 18-35 who tested positive for hepatitis C virus (HCV) RNA, 96% had conditions that are potentially unwarranted contraindications for HCV treatment ( e. g., problem drinking, moderate-to-severe depression, and recent drug injection). Restrictive eligibility criteria may deny treatment to a large proportion of patients who could benefit from it.

引用

页码：669 / 672

页数：4

共 50 条

[21] Hepatitis C virus infection among Alaskan drug users
Fisher, DG
Fenaughty, AM
Paschane, AA
Paschane, DM
Cagle, HH
Orr, SM
AMERICAN JOURNAL OF PUBLIC HEALTH, 1997, 87 (10) : 1722 - 1724
[22] First injection of ketamine among young injection drug users (IDUs) in three US cities
Lankenau, Stephen E.
Sanders, Bill
Bloom, Jennifer Jackson
Hathazi, Dodi
Alarcon, Erica
Tortu, Stephanie
Clatts, Michael C.
DRUG AND ALCOHOL DEPENDENCE, 2007, 87 (2-3) : 183 - 193
[23] Factors associated with interest in initiating treatment for hepatitis C virus (HCV) infection among young HCV-infected injection drug users
Strathdee, SA
Latka, M
Campbell, J
O'Driscoll, PT
Golub, ET
Kapadia, F
Pollini, RA
Garfein, RS
Thomas, DL
Hagan, H
CLINICAL INFECTIOUS DISEASES, 2005, 40 : S304 - S312
[24] Hepatitis C Virus Infection and Related Risk Factors among Injection Drug Users in Montenegro
Bacak, Valerio
Lausevic, Dragan
Mugosa, Boban
Vratnica, Zoran
Terzic, Natasa
EUROPEAN ADDICTION RESEARCH, 2013, 19 (02) : 68 - 73
[25] The importance of preventing hepatitis C virus infection among injection drug users in the United States
Alter, MJ
Moyer, LA
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1998, 18 : S6 - S10
[26] Hepatitis C virus infection among injection drug users - Survival analysis of time to seroconversion
Hagan, H
Thiede, H
Des Jarlais, DC
EPIDEMIOLOGY, 2004, 15 (05) : 543 - 549
[27] Recommendations for the management of hepatitis C virus infection in injection drug users
Grebely, Jason
Robaeys, Geert
Bruggmann, Philip
Aghemo, Alessio
Backmund, Markus
Bruneau, Julie
Byrne, Jude
Dalgard, Olav
Feld, Jordan J.
Hellard, Margaret
Hickman, Matthew
Kautz, Achim
Litwin, Alain
Lloyd, Andrew R.
Mauss, Stefan
Prins, Maria
Swan, Tracy
Schaefer, Martin
Taylor, Lynn E.
Dore, Gregory J.
INTERNATIONAL JOURNAL OF DRUG POLICY, 2023, 111
[28] Acute hepatitis C virus infection in incarcerated injection drug users
McGovern, Barbara H.
Wurcel, Alysse
Kim, Arthur Y.
zur Wiesch, Julian Schulze
Bica, Ioana
Zaman, M. Tauheed
Timm, Joerg
Walker, Bruce D.
Lauer, Georg M.
CLINICAL INFECTIOUS DISEASES, 2006, 42 (12) : 1663 - 1670
[29] INFLUENCE OF F PROTEIN ON OUTCOME OF HEPATITIS C VIRUS INFECTION AMONG INJECTION DRUG USERS
Wang Jie
Zhang Yun
Yang Jingjing
Deng Xiaozhao
Cao Min
Yu Rongbin
Xu Ke
Wang Haopeng
PROGRESS ON POST-GENOME TECHNOLOGIES AND MODERN NATURAL PRODUCTS, 2011, 2011, : 415 - 418
[30] Hepatitis C Virus Infection among Injection Drug Users with and without Human Immunodeficiency Virus Co-Infection
Hsieh, Meng-Hsuan
Tsai, Jih-Jin
Hsieh, Ming-Yen
Huang, Chung-Feng
Yeh, Ming-Lun
Yang, Jeng-Fu
Chang, Ko
Lin, Wei-Ru
Lin, Chun-Yu
Chen, Tun-Chieh
Huang, Jee-Fu
Dai, Chia-Yen
Yu, Ming-Lung
Chuang, Wan-Long
PLOS ONE, 2014, 9 (04):

← 1 2 3 4 5 →